Site-independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumours

• Published in: The Journal of pathology 2004-04, Vol.202 (4), p.421-429
• Main Authors: Gunawan, Bastian, Schulten, Hans-Jürgen, von Heydebreck, Anja, Schmidt, Bettina, Enders, Christina, Höer, Jörg, Langer, Claus, Schüler, Phillip, Schindler, Christian G, Kuhlgatz, Jens, Füzesi, László
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; CGH; Chromosome Deletion; Chromosomes, Human, Pair 9 - genetics; Disease Progression; Disease-Free Survival; DNA, Neoplasm - genetics; Female; follow-up; Follow-Up Studies; Gastrointestinal Neoplasms - genetics; Gastrointestinal Neoplasms - pathology; gastrointestinal stromal tumour; General aspects; genetics; Humans; Intestinal Neoplasms - genetics; Intestinal Neoplasms - pathology; Karyotyping; Male; Medical sciences; Mesenchymoma - genetics; Mesenchymoma - pathology; Middle Aged; Nucleic Acid Hybridization; Prognosis; prognostication; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Survival Analysis
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.1537

Although the significance of tumour site for estimating malignant potential in gastrointestinal stromal tumours (GISTs) has recently been recognized, site‐specific genetic patterns have not to date been defined. This study examined 52 c‐kit‐positive primary GISTs (with a mean follow‐up of 42.3 months in 51 cases) from three different locations (35 gastric, 12 small intestinal, and five colorectal) using comparative genomic hybridization (CGH). In general, tumour site correlated with key prognostic factors, including tumour size, mitotic rate, proliferative activity, and probable malignant potential. Furthermore, several DNA copy number changes showed a site‐dependent pattern. These included losses at 14q (gastric 83%, intestinal 35%; p = 0.001), losses at 22q (gastric 46%, intestinal 82%; p = 0.02), losses at 1p (gastric 23%, intestinal 88%; p = 1 × 10−5), losses at 15q (gastric 14%, intestinal 59%; p = 0.002), losses at 9q (gastric 14%, intestinal 53%; p = 0.006), and gains at 5p (gastric 11%, intestinal 53%; p = 0.002). These data demonstrate strong site‐dependent genetic heterogeneity in GISTs that may form a basis for subclassification. Prognostic evaluation of DNA copy number changes identified losses at 9q as a site‐independent prognostic marker associated with shorter disease‐free survival (p = 0.03) and overall survival (p = 0.002). Furthermore, 9q loss also appeared to carry prognostic value in predicting overall survival for patients with advanced or progressive GISTs (p = 0.003). Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.